In the article by Tubach et al in the July 2009 issue of Arthritis & Rheumatism (pages 1884–1894), the name of the fourteenth author was spelled incorrectly. The author's correct name is O. Lortholary. Also, the term “anti-TNF therapy” was erroneously changed to “anti-TNF mAb therapy” at a late proof stage; “anti-TNF mAb therapy should read simply “anti-TNF therapy” in the following instances: page 1884 line 2 of left column and lines 1, 3, and 11 of right column, page 1885 line 5 of left column and lines 3, 6, 8, 12, 17, 22, and 28 of right column, page 1886 lines 16 and 26 of left column and last line of right column, page 1887 lines 1, 24, and 41 of left column, page 1888 lines 11, 13, 20, and 25 of left column and lines 4, 11, and 16 of right column, page 1889 lines 4 and 36 of right column, page 1891 line 15 of left column, page 1892 line 3 of right column (“anti-TNF mAb therapy” is correct in the other instances where it appears).

In the title of the article by Meinecke et al in the July 2009 issue of Arthritis & Rheumatism (pages 2065–2070), the term “The Small Ubiquitin-like Modifier” should have been “Small Ubiquitin-like Modifier 1”; thus, the correct title should be “Small Ubiquitin-like Modifier 1 Mediates the Resistance of Prosthesis-Loosening Fibroblast-like Synoviocytes Against Fas-Induced Apoptosis.”

We regret the errors.